Loading...
XNAS
BCDA
Market cap7mUSD
Dec 05, Last price  
1.37USD
1D
-6.80%
1Q
-33.50%
Jan 2017
-91.54%
Name

BioCardia Inc

Chart & Performance

D1W1MN
XNAS:BCDA chart
P/E
—
P/S
136.97
EPS
—
Div Yield, %
—
Shrs. gr., 5y
48.79%
Rev. gr., 5y
-39.41%
Revenues
58k
-87.84%
0001,268,0001,869,000012,00062,000268,000427,000517,000576,000479,000625,000710,000145,0001,015,0001,352,000477,00058,000
Net income
-8m
L-31.33%
-812,341-92,804-75,444-5,800,000-5,078,000-11,509,0009,662,000305,00019,000234,000322,000-10,310,000-12,308,000-13,872,000-14,819,000-15,005,000-12,621,000-11,913,000-11,571,000-7,946,000
CFO
-8m
L-19.53%
-455,817-741,464-47,123-2,696,000-4,783,000-4,277,000-3,087,000-310,00027,000214,000331,000-5,522,000-8,671,000-11,069,000-9,445,000-12,357,000-10,366,000-10,561,000-9,974,000-8,026,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
URL
https://www.biocardia.com/
IPO date
Nov 13, 1996
Employees
30
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT